Potential for pantoprazole use in the therapy of gastroesophageal reflux disease
- Authors: Loginov AF1, Loginov AF1
-
Affiliations:
- Issue: No 13 (2009)
- Pages: 29-33
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/277434
- ID: 277434
Cite item
Full Text
Abstract
Erosive esophagitis is one of the most severe clinical forms of gastroesophageal reflux disease (GERD), a lifelong health condition, which occurs as a result of gastric juice reflux into the esophagus. More than 40% of the adult population has GERD symptoms, expressed in varying degrees and the registered at least 2 times a week. GERD-induced esophagus damage can cause more serious complications, such as stricture, bleeding, and the precancer formation - Barrett's esophagus. In GERD treatment the drugs of choice are the modern acid production blockers (proton pump inhibitors, PPI). The analysis of the literature data for optimal choice of PPIs for the GERD treatment highlights the advantages of pantoprazole. We consider the metabolism characteristics of this drug administration in standard doses in comparison with other PPIs.
References
- Гастроэнтерология и гепатология: диагностика и лечение / Под ред. А.В. Калинина, А.И. Хазанова. М., 2006. 602 с.
- Ивашкин В.Т., Трухманов А.С. Современный подход к терапии гастроэзофагеальной рефлюксной болезни во врачебной практике / РМЖ. 2003. № 2. С. 43-48.
- Ивашкин В.Т., Шептулин А.А. Избранные лекции по гастроэнтерологии. М., 2001.
- Исаков В.А. Безопасность ингибиторов протонного насоса при длительном применении // Клиническая фармакология и терапия. 2004. № 13(1). С. 26-32.
- Пиманов С.И. Эзофагит, гастрит и язвенная болезнь. Руководство для врачей. М., 2000.
- Профилактика и лечение хронических заболеваний верхних отделов желудочно-кишечного тракта / Под ред. акад. РАМН В.Т. Ивашкина. М., 2002. 128 с.
- Beil W, Staar U, Sewing K. Pantoprazole: a novel H+/K+-ATPase inhibitor with an improved pH stability. Eur J Pharmacol 1992;218:265-71.
- Besancon M, Simon A, Sachs G, et al. Sites of reaction of the gastric H,K-ATPase with eхtracutoplasmic thiol reagents. J Biol Chem 1997;272:22438-46.
- Castell DO, et al. The next era in the management of esophageal reflux: A concise review. New dimensions in understanding reflux mechanisms: The evolving role of impedance monitoring; 12th United European Gastroenterology Week, Prague, Czech Republic, 2004.
- Grass U. Drug interactions with proton pump inhibitors. Der Kassenarzt 2000;43: 32-9.
- Dent J, Brun A, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval workshop report. Gut 1999;44:S1-S16.
- FDA approves tablet formulation of Protonix (pantoprazole sodium), а new proton pump inhibitor for the treatment of erosive esophagitis. Madison, NJ: American Home Products, 2000.
- Grass U. Drug interactions with proton pump inhibitors. Der Kassenarzt 2000;43:32-39.
- Heinze H, Preinfalk J, Athmann C, et al. Clinical efficacy and safety of pantoprasole in severe acid-peptic disease during up to 10 years maintenanse treatment. Gut 2003;52(Suppl. VI):A63.
- Katashima M, Yamamoto K, Tokuma Y, еt al. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lanzoprazole and pantoprazole, in humans. Eur J Drug Metabol Pharmacokinet 1998;23:19-26.
- Protonix (pantoprazole sodium) delayed-release tablets package insert. Philadelphia: Wyeth Laboratories; 2000.
- Sachs G. Synthesis or Rupture: duration of acid inhibition by PPIs. Research Highlights Driving Therapeutic Advance. ALTA-NA Pharma Symposium. 2002;9-10.
- Sifrim DD, et al. Gastro-oesophageal reflux monitoring: Review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004;53:1024-31.
- Smout AJ. Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther 1997;11(Suppl. 2):81-85.
- Stanghellini V, Cogliandro R, Cogliandro L, et al. Unsolved problems in the management of patients with gastro-oesophageal reflux disease. Digestive and Liver Disease 2002;34:843-48.
- Varil N, Fennerty M. Systematic review: direct comparative trialsof the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 2002;16:1301-07.
Supplementary files
